Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison.

Peking University People's Hospital, Institute of Hematology, Beijing, People's Republic of China.
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation (Impact Factor: 3.15). 06/2011; 17(6):821-30. DOI: 10.1016/j.bbmt.2010.08.023
Source: PubMed

ABSTRACT The outcomes of an historic comparison of 117 consecutive, high-risk, acute leukemia patients undergoing hematopoietic stem cell transplantation (HSCT) from HLA-mismatched/haploidentical donors (HID, n = 81) or HLA-identical sibling donors (ISD, n = 36) without the use of in vitro T cell depletion (TCD), between the period of January 2005 and April 2009 were compared. Full engraftment was achieved in 98% of patients in the HID group and 97% in the ISD group. The cumulative incidences of grades II-IV acute graft-versus-host disease (aGVHD) in the HID and ISD cohorts were 49% and 24%, respectively (P = .014) with a relative risk (RR) of 2.99 (1.25-7.21) (P = .014). The incidence of chronic GVHD (cGVHD) did not differ significantly between the 2 cohorts. The 2-year cumulative incidence of relapse was significantly lower in HID (26%) than in ISD patients (49%) (P = .008). The 2-year cumulative incidence of nonrelapse mortality (NRM) was comparable in recipients of HID (34%) and ISD grafts (38%) (P = .85). The 3-year probability of overall survival (OS) was higher in HID patients (42%) than in ISD (20%) (P = .048) patients. Our comparisons suggest that HID transplants can achieve a stronger graft-versus-leukemia (GVL) effect than ISD for high-risk acute leukemia patients.

  • [Show abstract] [Hide abstract]
    ABSTRACT: This study included data from 185 consecutively treated patients, 16 years of age or older, who underwent myeloablative transplantation using unrelated umbilical cord blood (UCB) (UCB transplantation (UCBT), n=70) or HLA-identical sibling donor peripheral blood stem cells alone or combined with bone marrow (BMT/PBSCT, n=115) from October 2001 to December 2012. All patients received myeloablative regimens, cyclosporin A plus mycophenolate mofetil as prophylaxis for GVHD, and similar supportive care. Although hematopoietic recovery was significantly delayed after UCBT, the rate of neutrophil engraftment was comparable. The median follow-up was 53 months (range, 15-136 months) for BMT/peripheral blood SCT (PBSCT) recipients and 35 months (range, 10-123 months) for UCBT recipients. There were no significant differences in the cumulative incidence of grades III to IV acute GVHD, relapse rate, or 3-year probabilities of disease-free survival between patients receiving UCBT and those receiving BMT/PBSCT. However, the cumulative incidence of chronic and extensive chronic GVHD was lower in UCBT recipients. The rates of long-term survivors returning to school or work and off immunosuppressive therapy were significantly higher after UCBT, which indicated that long-term survivors who underwent UCBT had a higher quality of life.Bone Marrow Transplantation advance online publication, 19 May 2014; doi:10.1038/bmt.2014.102.
    Bone marrow transplantation. 05/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Loss of mismatched HLA is a cause of relapse following HLA-mismatched allo-SCT. We directly detected the loss of mismatched HLA alleles in relapsed leukemic cells at a MRD level using HLA typing by multicolor FACS (HLA-Flow) in combination with FISH in the BM of two patients with MLL-AF9-positive AML, at 6 and 10 months after mismatched allo-SCT. HLA-Flow with FISH analysis detected relapsed leukemic cells not expressing a mismatched HLA allele and harboring the MLL rearrangement. Simultaneously, real-time quantitative RT-PCR detected a low copy number of MLL-AF9 transcripts, consistent with MRD detection. HLA-Flow with FISH is a powerful method for detecting molecular relapse after mismatched allo-SCT and provides important information on the HLA expression status of the relapsed leukemic cells to help determine the next intervention.
    Pediatric Transplantation 05/2014; · 1.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To compare the efficacy of haploidentical hematopoietic stem cell transplantation (HSCT) with chemotherapy alone in adult standard-risk acute lymphoblastic leukemia (ALL) in first complete remission (CR1). Consecutive 138 adult patients with standard-risk ALL in CR1 were retrospectively investigated. Out of these patients, 59 received chemotherapy alone (Group A), and 79 received unmanipulated haploidentical HSCT (Group B). Cumulative incidence of relapse at 5 years in Group A was significantly higher than Group B (66.3%vs.29.9%,P<0.0001). The OS and DFS in Group A were significantly inferior to Group B (P<0.0001). Moreover, multivariate analyses demonstrated that central nervous system leukemia (P=0.002), T-cell immunophenotype (P=0.044), expression of E2A-PBX1 (P=0.007) and minimal residual disease-positive after the 1(st) cycle of consolidation (P=0.004) were correlated with relapse. Patients with one of four risk factors were assigned to high-risk group. Otherwise, patients without risk factors were assigned to low-risk group. In high-risk group, HSCT had lower relapse rate and superior DFS compared with chemotherapy (P<0.05), but in low-risk group, there were no differences between HSCT and chemotherapy (P>0.05). This study is the first to demonstrate that, compared with chemotherapy alone, haploidentical HSCT is a better post-remission therapy in adult standard-risk ALL in CR1. Moreover, based on the four risk factors, the establishment of risk-stratification could identify the subgroup of patients with higher risk of relapse in adult standard-risk ALL in CR1. Furthermore, risk-stratification directed post-remission therapies using haploidentical HSCT or chemotherapy alone not only reduce relapse rate, but also avoid unnecessary treatment-related mortality and improve survival.
    Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 04/2014; · 3.15 Impact Factor